Role for <sup>11</sup>C-choline PET in active surveillance of prostate cancer

Authors

  • Oleksandr Boychak Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Larissa Joy Vos Department of Oncology, University of Alberta
  • William Makis Division of Nuclear Medicine, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Francois-Alexandre Buteau Division of Nuclear Medicine, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Nadeem Pervez Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Matthew Parliament Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Alexander JB McEwan Division of Nuclear Medicine, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  • Nawaid Usmani Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

DOI:

https://doi.org/10.5489/cuaj.2380

Keywords:

Prostate cancer, Active surveillance, 11C-choline, Positron Emission Tomography (PET)

Abstract

Introduction: Active surveillance (AS) is an increasingly popular management strategy for men diagnosed with low-risk indolent prostate cancer. Current tests (prostate-specific antigen [PSA], clinical staging, and prostate biopsies) to monitor indolent disease lack accuracy. 11C-choline positron emission tomography (PET) has excellent detection rates in local and distant recurrence of prostate cancer. We examine 11C-choline PET for identifying aggressive prostate cancer warranting treatment in the AS setting.

Methods: In total, 24 patients on AS had clinical assessment and PSA testing every 6 months and 11C-choline PET and prostate biopsies annually. The sensitivity and specificity to identify prostate cancer and progressive disease (PD) were calculated for each 11C-choline PET scan.

Results: In total, 62 biopsy-paired, serial 11C-choline PET scans were analyzed using a series of standard uptake value-maximum (SUVmax) cut-off thresholds. During follow-up (mean 25.3 months), 11 of the 24 low-risk prostate cancer patients developed PD and received definitive treatment. The prostate cancer detection rate with 11C-choline PET had moderate sensitivity (72.1%), but low specificity (45.0%). PD prediction from baseline 11C-choline PET had satisfactory sensitivity (81.8%), but low specificity (38.5%). The addition of clinical parameters to the baseline 11C-choline PET improved specificity (69.2%), with a slight reduction in sensitivity (72.7%) for PD prediction.

Conclusions: Addition of 11C-choline PET imaging during AS may help to identify aggressive disease earlier than traditional methods. However, 11C-choline PET alone has low specificity due to overlap of SUV values with benign pathologies. Triaging low-risk prostate cancer patients into AS versus therapy will require further optimization of PET protocols or consideration of alternative strategies (i.e., magnetic resonance imaging, biomarkers).

Downloads

Download data is not yet available.

Downloads

Published

2015-03-11

How to Cite

Boychak, O., Vos, L. J., Makis, W., Buteau, F.-A., Pervez, N., Parliament, M., McEwan, A. J., & Usmani, N. (2015). Role for <sup>11</sup>C-choline PET in active surveillance of prostate cancer. Canadian Urological Association Journal, 9(3-4), e98–103. https://doi.org/10.5489/cuaj.2380

Issue

Section

Original Research